Amarin Corp Plc (AMRN)

[ziploc_1]

"Biogen loses 18 billion in market value after ending Alzheimer trial"

"Biogen has made a long-term commitment to furthering Alzheimer’s disease research and treatment. Our vision is to redefine Alzheimer’s Disease through innovative medicines to improve the lives of patients and their caregivers.

With an emphasis on early-stage disease, our research programs target several of the identified causes, amyloid and tau pathology – proteins believed to play a critical role in Alzheimer’s disease development. These programs range from preclinical experiments to Phase 3 clinical trials.

Our lead Alzheimer’s disease candidate, currently under development, is aducanumab, the first investigational drug to slow progression and reduce biological evidence of disease in an early clinical trial. We hope that aducanumab will be the first approved therapy to meaningfully change the course of Alzheimer’s Disease and significantly improve the lives of Alzheimer’s patients and their families."

This 18 billion IMO could have been better spent on research using Vascepa to treat Alzheimers...rather than this monoclonal antibody treatment, which is unsafe, expensive, and inconvenient(especially for older people)